The 33rd European Urology Congress (EAU 2018) closed its doors yesterday in Copenhagen with excellent figures: 15,000 urologists, 160 companies and 2,000 business representatives. Devicare has been present in the exhibition area together with one of its international partners presenting Lit-Control®, the first medical solution which allows recurrent urinary diseases to be effectively addressed with an innovative solution enabling patients to check their own urinary pH with remote monitoring.
Últimas notas de prensa de Devicare
Devicare has obtained the patent in Spain for a new electrochemical ion sensor, which is the most advanced of its type on the market, improving the features of the Lit-Control pH Meter® medical device for self-monitoring chronic urological diseases (lithiasis, infections, overactive bladder, calcification of urinary catheters, etc.). Specifically, the sensor incorporates a reference electrode that prevents it from drying after its use.
Devicare has signed a participative loan worth 2 million Euros from the Innova Global line by Avançsa, assigned to the Business and Expertise Department, with the option to convert the investment into Series A stock in the mid-term. With this new economic injection, Devicare will continue the strategic development and validation plan of new medical solutions under the Remote Patient Monitoring concept...
Sensors are changing our lives, also in healthcare (for the better). During the opening ceremony of the Healthcare and Social ICT R+D+I Conference held in the University of Vic on 28 September, Marina Geli, coordinator of the Healthcare and Social Studies Centre (CESS), highlighted that sensor technology is essential to advance patient empowerment in the home.
This week Vienna is hosting the largest European Urolithiasis Meeting, organised every two years by the European Association of Urology (EAU). The event will bring together opinion leaders and experts who will present the latest international scientific advances to improve the treatment of this disease.
Devicare has revamped the websites for their two medical solutions that are unique on the market (first-in-class): Tao-Control® for chronic anticoagulated patients and the Lit-Control® product line for urinary health.
The Catalan Finance Institute (ICF), in collaboration with ACCIÓ (Agency for business competitiveness of the Generalitat of Catalonia), granted Devicare participation loan of 133,000 euros as part of the Corporate Entrepreneurship Programme in order to join...
The Association of Out-Patient Clinics and Entities of the Community of Madrid (ACESIMA) and Devicare have signed a strategic collaboration agreement to promote R&D&I and the use and training of innovative healthcare services and technologies intended for the in-home self-management of chronic patients in therapeutic fields such as the cardiovascular and urological fields, among others.
UIB, the Hospital de Manacor and Devicare launch a study to evaluate the effect of theobromine, the first inhibitor that prevents renal lithiasis
The Laboratory of Renal Lithiasis Research at the University of the Balearic Islands (UIB) will carry out a study among patients to evaluate the effects of theobromine, a substance that acts as an inhibitor of uric acid crystallisation in urine and that was patented as a dietary supplement by the UIB research team led by Dr. Fèlix Grases. The study will be carried out in collaboration with the Urology Service of the Hospital de Manacor,...
Devicare has joined the Associate Collaborators' Forum (FAC) of The Catalan Hospitals Union (La Unió), a body made up of more than 25 industrial and service companies that operate in the health, social and attention to dependency fields. Through this forum, La Unió aims to promote the relationship between the associate collaborators, such as Devicare, and the health and social centers of Catalonia in order to encourage partnerships for innovation in management and also strengthen the role of business lobbying in the sector.